DE602005008071D1 - C-terminale modifikation von polypeptiden - Google Patents

C-terminale modifikation von polypeptiden

Info

Publication number
DE602005008071D1
DE602005008071D1 DE602005008071T DE602005008071T DE602005008071D1 DE 602005008071 D1 DE602005008071 D1 DE 602005008071D1 DE 602005008071 T DE602005008071 T DE 602005008071T DE 602005008071 T DE602005008071 T DE 602005008071T DE 602005008071 D1 DE602005008071 D1 DE 602005008071D1
Authority
DE
Germany
Prior art keywords
polypeptides
trypsin
xaa2
terminal modification
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005008071T
Other languages
English (en)
Inventor
Eva Hoess
Frank Bordusa
Rupert Herrmann
Hans-Dieter Jakubke
Wilhelm Tischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Unilever NV
Original Assignee
F Hoffmann La Roche AG
Unilever NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Unilever NV filed Critical F Hoffmann La Roche AG
Publication of DE602005008071D1 publication Critical patent/DE602005008071D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6427—Chymotrypsins (3.4.21.1; 3.4.21.2); Trypsin (3.4.21.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
DE602005008071T 2004-08-13 2005-08-12 C-terminale modifikation von polypeptiden Active DE602005008071D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04019237 2004-08-13
PCT/EP2005/008809 WO2006015879A1 (en) 2004-08-13 2005-08-12 C-terminal modification of polypeptides

Publications (1)

Publication Number Publication Date
DE602005008071D1 true DE602005008071D1 (de) 2008-08-21

Family

ID=34926160

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005008071T Active DE602005008071D1 (de) 2004-08-13 2005-08-12 C-terminale modifikation von polypeptiden

Country Status (10)

Country Link
US (2) US20080064079A1 (de)
EP (1) EP1778839B1 (de)
JP (1) JP4538501B2 (de)
CN (1) CN101010425B (de)
AT (1) ATE400647T1 (de)
CA (1) CA2569707C (de)
DE (1) DE602005008071D1 (de)
ES (1) ES2309785T3 (de)
HK (1) HK1110888A1 (de)
WO (1) WO2006015879A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005046113A1 (de) 2005-09-27 2007-03-29 Sanofi-Aventis Deutschland Gmbh Verfahren zur Amidierung von Polypetiden mit C-terminalen basischen Aminosäuren unter Verwendung spezifischer Endoproteasen
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
DE102006031955A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
RS56632B1 (sr) 2008-10-17 2018-03-30 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
EP2417155B1 (de) 2009-04-06 2013-06-19 Novo Nordisk A/S Gezielte fresetzung von faktor-viii-proteinen auf thrombozyten
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
JP5749744B2 (ja) * 2010-02-11 2015-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｉｇｆ−ｉポリ（エチレングリコール）コンジュゲート
JP6199186B2 (ja) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ２型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
MX2017007699A (es) 2014-12-12 2017-09-18 Sanofi Aventis Deutschland Formulacion de proporcion fija de insulina glargina/lixisenatida.
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
EP3650541A1 (de) 2018-11-08 2020-05-13 BioPharma Translationsinstitut Dessau Forschungs GmbH Trypsin-mutante zur c- und n-terminalen modifizierung von polypeptiden
CN113227369A (zh) * 2018-12-19 2021-08-06 生物制药翻译学院德绍研究有限公司 具有改善的酶学特性的胰蛋白酶变体
AU2020399194A1 (en) 2019-12-10 2022-07-28 Sanofi A method of forming a conjugate of a sulfonamide and a polypeptide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9001705D0 (sv) * 1990-05-11 1990-05-11 Medscand Ab Saett foer diagnostik av virusbaerande tumoerer genom immunoassay
US5580751A (en) * 1990-09-14 1996-12-03 Carlsberg A/S Process for the preparation of C-terminally amidated peptides
AU6171594A (en) 1993-02-04 1994-08-29 Genentech Inc. Serine protease variants having peptide ligase activity
US6187579B1 (en) * 1993-10-28 2001-02-13 Carlsberg A/S Customized proteases
US5958783A (en) 1994-07-25 1999-09-28 Roche Diagnostics Gmbh Metal complexes with a charged linker
US5985627A (en) 1997-02-28 1999-11-16 Carlsberg Laboratory Modified carboxypeptidase
DE10049673A1 (de) * 2000-10-07 2002-04-25 Univ Leipzig Verfahren zur Herstellung von Peptiden, Peptidmimetika und Proteinen
CN1354253A (zh) * 2001-12-24 2002-06-19 南京医科大学 淡色库蚊胰蛋白酶基因

Also Published As

Publication number Publication date
CA2569707C (en) 2013-09-24
US8927230B2 (en) 2015-01-06
WO2006015879A1 (en) 2006-02-16
JP4538501B2 (ja) 2010-09-08
ATE400647T1 (de) 2008-07-15
CA2569707A1 (en) 2006-02-16
EP1778839A1 (de) 2007-05-02
EP1778839B1 (de) 2008-07-09
US20080064079A1 (en) 2008-03-13
CN101010425B (zh) 2010-05-26
CN101010425A (zh) 2007-08-01
ES2309785T3 (es) 2008-12-16
US20130177940A1 (en) 2013-07-11
HK1110888A1 (en) 2008-07-25
JP2008508871A (ja) 2008-03-27

Similar Documents

Publication Publication Date Title
ATE400647T1 (de) C-terminale modifikation von polypeptiden
FR2831170B1 (fr) Proteines c modifiees activables directement par la thrombine
MY148447A (en) Method for amidating polypeptides with basic aminoacid d-terminals by means of specific endoproteases
NZ597685A (en) Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
IN2014CN02050A (de)
BRPI0606612A2 (pt) expressão recombinante de proteìnas em uma forma de duas cadeias ligadas por dissulfeto
DK1144607T5 (da) Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
NO20074374L (no) Fremgangsmate for fremstilling av polypeptidblandinger ved anvendelse av hydrogenolyse
NZ593837A (en) Recombinantly modified plasmin
CA2443365A1 (en) Methods for the recombinant production of antifusogenic peptides
EP2348053A3 (de) Oligopeptid-Liganden
MXPA03000786A (es) Peptidos de promiostatina y metodos de usar los mismos.
ATE398179T1 (de) Von rna polymerasen abstammende polypeptide und ihre verwendungen
WO2002038742A3 (en) Dipeptidylpeptidases and methods of use
EP2014676A4 (de) Mutante des hgf-precursor-proteins und aktivierte form davon
MX2018009216A (es) Metodo para producir un hidrolizado de proteina empleando una tripeptidil peptidasa de aspergillus fumigatus.
DE60134230D1 (de) Substraten und nachweise zur wirksamkeit von beta-secretase
NZ601647A (en) Variant hhip1 protein and methods and uses thereof
ATE538806T1 (de) Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren
ATE485831T1 (de) Behandlung von neurodegeneration
BRPI0715331B8 (pt) polipeptídeo que compreende uma porção n-terminal e uma porção c-terminal, e uso do mesmo
EP1915617A4 (de) Verfahren und zusammensetzungen zur identifizierung eines peptids mit intermolekularer wechselwirkung mit einem interessierenden ziel
SG170757A1 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
WO2009118710A3 (en) Cd4-related polypeptides and methods of use
WO2021188869A3 (en) Determination of free n-terminus of pegfilgrastim using an acid protease

Legal Events

Date Code Title Description
8364 No opposition during term of opposition